Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Multicohort, Phase 1/2 Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors

Next Previous
Trial Profile

An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Multicohort, Phase 1/2 Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 22 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs INBRX 106 (Primary) ; Pembrolizumab (Primary) ; Carboplatin; Cisplatin; Paclitaxel; Pemetrexed
  • Indications Adenocarcinoma; Gastric cancer; Head and neck cancer; Malignant melanoma; Nasopharyngeal cancer; Non-small cell lung cancer; Oesophageal cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Urogenital cancer; Uveal melanoma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Inhibrx

Most Recent Events

  • 18 Dec 2025 Status changed from recruiting to active, no longer recruiting.
  • 16 Dec 2025 According to an Inhibrx media release, company provided a brief progress update on the expansion cohorts investigating ozekibart in combination with FOLFIRI for late-line colorectal cancer and with irinotecan and temozolomide for refractory Ewing sarcoma.
  • 16 Dec 2025 According to an Inhibrx media release, enrollment of 34 patients was completed in November 2025. Data are not yet mature but are expected to be interpretable in the second half of 2026 to assess efficacy and clinical benefit. Progression-free survival data are expected to mature in Q2 2026, and the company plans to provide an update at that time.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top